Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Janus kinase (JAK) inhibition is a primary treatment for myelofibrosis (MF) and is used for polycythemia vera (PV) and essential thrombocythemia (ET).
• Ruxolitinib, a JAK inhibitor, effectively reduces splenomegaly and symptoms in MF and controls hematocrit in PV, but its disease-modifying impact is limited.
• Current treatments for PV, like hydroxyurea (HU) and interferons, have limitations, and JAK inhibitors do not prevent disease progression to MF or acute myeloid leukemia (AML).

Purpose of the Study:

• To review novel agents studied as monotherapy for MF, particularly in cases of JAK inhibitor resistance or intolerance.
• To discuss emerging compounds under development for PV and ET.
• To highlight the limitations of current therapies and the need for new treatment strategies in classic myeloproliferative neoplasms (MPNs).

Main Methods:

• Review of clinical studies and literature on novel therapeutic agents for MF, PV, and ET.
• Focus on agents studied as monotherapy in MF post-JAK inhibitor treatment.
• Examination of new compounds targeting these myeloproliferative neoplasms.

Main Results:

• JAK inhibitors show benefits in symptom control but limited effects on bone marrow fibrosis and allele burden in MF.
• Ruxolitinib effectively manages PV symptoms and hematocrit but has not convincingly reduced thromboembolic events.
• Numerous novel agents with diverse mechanisms of action are in development for MF, PV, and ET.

Conclusions:

• While JAK inhibitors are crucial for managing MPNs, their disease-modifying capacity is restricted.
• There is a significant need for novel therapeutic strategies to improve outcomes and overcome resistance in MF, PV, and ET.
• Ongoing research into new agents holds promise for advancing the treatment landscape of these hematologic malignancies.